SCHEDULE 13D: Access Industries Affiliates Boost Stake in Zura Bio to 19.9% Through Strategic Transactions

Access Industries affiliates, including AI Biotechnology LLC and Len Blavatnik, have increased their beneficial ownership in Zura Bio Limited to 19.9% through a series of share and warrant transactions.

Summary

• The Reporting Persons (AI Biotechnology LLC, Access Industries Holdings LLC, Access Industries Management, LLC, and Len Blavatnik) have filed a Schedule 13D, superseding previous 13G filings, to report their beneficial ownership in Zura Bio Limited.
• The Reporting Persons collectively beneficially own 14,326,090 Class A Ordinary Shares of Zura Bio Limited, representing 19.9% of the outstanding shares.
• This ownership comprises 4,552,725 Class A Ordinary Shares held directly by AI Biotechnology LLC (AIB) and 9,773,365 Class A Ordinary Shares issuable upon partial conversion of Private Placement Warrants held by AIB.
• The percentage is calculated based on 61,874,998 Class A Ordinary Shares outstanding as of March 31, 2025 (as reported in Zura Bio's Form 10-Q), plus the 9,773,365 issuable shares from warrants.
• Key transactions include AIB's purchase of 2,100,000 2023 Warrants at $4.25 per share in June 2023, 8,046,346 2024 Warrants at $3.108 per share in April 2024, and 3,000,000 Class A Ordinary Shares at $1.20 per share in April 2025.
• AIB also surrendered 3,000,000 Class A Ordinary Shares for no consideration in exchange for 3,000,000 2025 Warrants on April 17, 2025.
• The Reporting Persons acquired these securities as an investment in the regular course of their businesses and may engage in discussions with Zura Bio's management and board regarding business, operations, governance, and strategy.

Sentiment

Score: 7

Explanation: The filing demonstrates a continued and substantial strategic investment by Access Industries and Len Blavatnik in Zura Bio Limited, increasing their beneficial ownership to 19.9%. This indicates strong investor confidence and a long-term commitment, despite some complex share/warrant exchanges.

Positives

• Significant and continued investment by a major institutional investor (Access Industries) and its founder, Len Blavatnik, signals confidence in Zura Bio Limited.
• The increase in beneficial ownership to 19.9% indicates a strong, long-term strategic interest in the company.
• The presence of Dan Becker, Managing Director at Access Biotechnology, on Zura Bio's board suggests active engagement and oversight from a major investor.

Negatives

• The surrender of 3,000,000 Class A Ordinary Shares for no consideration in exchange for warrants, while part of a strategic move, represents a direct reduction in common share holdings for AIB at that specific point.
• The varying purchase prices, including a recent purchase at $1.20 per share, could indicate opportunistic buying at lower valuations or a declining share price trend.

Risks

• The 'Beneficial Ownership Blocker' limits the immediate exercise of warrants if it would cause AIB's beneficial ownership to exceed 9.99% (or 19.99% with 61 days' notice), potentially restricting AIB's ability to fully convert its warrants quickly.
• Future actions of the Reporting Persons, including potential disposal of all or a portion of their securities, could impact the Issuer's share price.

Future Outlook

The Reporting Persons intend to re-examine their investment periodically and may acquire additional securities or dispose of existing holdings, or enter into derivative transactions, based on prevailing market conditions, other investment opportunities, liquidity requirements, and the Issuer's prospects. They reserve the right to change their investment purpose or adopt new plans or proposals in the future.

Management Comments

• "The Reporting Persons who hold securities of the Issuer directly acquired those securities as an investment in the regular course of their businesses."
• "The Reporting Persons may engage in discussions with management, the Issuer's board of directors, other stockholders of the Issuer and other relevant parties concerning the business, operations, board composition, management, strategy and future plans of the Issuer."
• "The Reporting Persons intend to re-examine their investment from time to time and, depending on prevailing market conditions, other investment opportunities, liquidity requirements or other investment considerations the Reporting Persons deem material, the Reporting Persons may from time to time acquire additional securities of the Issuer in the open market, block trades, negotiated transactions, or otherwise and may also dispose of all or a portion of the Issuer's securities, in open market or privately negotiated transactions, and/or enter into derivative transactions with institutional counterparties with respect to the Issuer's securities, in each case, subject to limitations under applicable law."

Industry Context

This filing indicates continued strategic investment by a major player in the biopharmaceutical investment space (Access Biotechnology, part of Access Industries) into Zura Bio Limited. This suggests a belief in the long-term potential of Zura Bio's specific therapeutic areas or overall business model within the broader biotechnology industry.

Related Party Transactions

• AI Biotechnology LLC (AIB) purchased 500,000 Class A Ordinary Shares from Athanor Master Fund, LP and Athanor International Master Fund, LP on November 24, 2024.
• AIB purchased 3,000,000 Class A Ordinary Shares from Liminatus Pharma LLC on April 24, 2025.
• AIB engaged in a share surrender and warrant agreement with Zura Bio Limited on April 17, 2025.
• AIB entered into subscription agreements with Zura Bio Limited in April 2023 and April 2024.

Stakeholder Impact

• Shareholders: The increased significant stake by a major institutional investor could be viewed positively, signaling confidence and potentially stabilizing the stock. However, the investor's stated intent to potentially dispose of shares in the future introduces uncertainty.
• Management/Board: The Reporting Persons' stated intent to engage in discussions regarding business, operations, board composition, management, strategy, and future plans indicates potential influence on the company's direction.

Next Steps

• The Issuer is obligated to keep registration statements effective for resale of shares and warrant shares until certain conditions are met (e.g., Rule 144 eligibility, actual sale, or two years from effectiveness).
• Reporting Persons may engage in discussions with Zura Bio's management and board regarding business, operations, board composition, management, strategy, and future plans.
• Reporting Persons may acquire or dispose of additional securities of the Issuer in the future.

Key Dates

Recommendation

Keywords

Zura Bio Limited, Class A Ordinary Shares, Schedule 13D, AI Biotechnology LLC, Access Industries, Len Blavatnik, beneficial ownership, private placement warrants, SEC filing, investment, biotechnology, biopharmaceutical